Consolidated Statements of Changes in Stockholders’ Equity - USD ($) $ in Thousands	Series 1 Convertible Preferred Stock	Common Stock	Additional Paid-in Capital	Accumulated Deficit	Accumulated Other Comprehensive Loss	Total
Balance at Dec. 31, 2019		$ 3	$ 10,651	$ (12,782)		$ (2,128)
Balance (in Shares) at Dec. 31, 2019		2,627,533
Issuance of Common Stock in ArTara Private Placement, net of offering costs			1,867			1,867
Issuance of Common Stock in ArTara Private Placement, net of offering costs (in Shares)		284,875
Issuance of Common Stock in Proteon Private Placement, net of offering costs		$ 2	12,411			12,413
Issuance of Common Stock in Proteon Private Placement, net of offering costs (in Shares)		1,896,888
Issuance of Series 1 Convertible Preferred Stock in Proteon Private Placement, net of offering costs			25,319			25,319
Issuance of Series 1 Convertible Preferred Stock in Proteon Private Placement, net of offering costs (in Shares)	3,879
Reverse business combination		$ 1	34,532			34,533
Reverse business combination (in Shares)		1,033,907
Issuance of Common Stock in public offering, net of offering costs		$ 4	73,566			73,570
Issuance of Common Stock in public offering, net of offering costs (in Shares)		4,600,000
Issuance of Series 1 Convertible Preferred in public offering, net of offering costs			66,284			66,284
Issuance of Series 1 Convertible Preferred in public offering, net of offering costs (in Shares)	4,148
Issuance of Common Stock in Common Offering (Underwriters Overallotment Option), net of offering costs		$ 1	11,086			11,087
Issuance of Common Stock in Common Offering (Underwriters Overallotment Option), net of offering costs (in Shares)		690,000
Settlement of restricted stock units
Settlement of restricted stock units (in Shares)		20,870
Exercise of stock options			530			530
Exercise of stock options (in Shares)		57,767
Stock-based compensation expense			9,746			9,746
Stock-based compensation expense (in Shares)
Net loss				(33,978)		(33,978)
Balance at Dec. 31, 2020		$ 11	245,992	(46,760)		199,243
Balance (in Shares) at Dec. 31, 2020	8,027	11,211,840
Settlement of restricted stock units			(228)			(228)
Settlement of restricted stock units (in Shares)		23,891
Stock-based compensation expense			10,362			10,362
Stock-based compensation expense (in Shares)
Other comprehensive loss					(211)	(211)
Other comprehensive loss (in Shares)
Net loss				(47,252)		(47,252)
Balance at Dec. 31, 2021		$ 11	$ 256,126	$ (94,012)	$ (211)	$ 161,914
Balance (in Shares) at Dec. 31, 2021	8,027	11,235,731